NPS CEO gives insight into orphan drug pricing

01/7/2013 | Forbes

When pricing a new biologic drug, developers consider medical value, direct and indirect costs, market size and insurers' willingness to pay, NPS Pharmaceuticals CEO Francois Nader said. In the case of drugs to treat rare diseases, such as NPS' Gattex, NPS will give grants to rare-disease organizations that will help patients pay, and the company will offer copay assistance.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI